Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia

Sponsor
Novartis Pharmaceuticals (Industry)
Overall Status
Completed
CT.gov ID
NCT00099216
Collaborator
(none)
708
63
51
11.2
0.2

Study Details

Study Description

Brief Summary

The goal of this research study is to evaluate the effectiveness, tolerability and safety of rivastigmine capsules in males and females between the ages of 50 and 85 years old with probable vascular dementia.

Condition or Disease Intervention/Treatment Phase
Phase 3

Study Design

Study Type:
Interventional
Actual Enrollment :
708 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double
Primary Purpose:
Treatment
Official Title:
Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia
Study Start Date :
Aug 1, 2001
Actual Primary Completion Date :
Nov 1, 2005
Actual Study Completion Date :
Nov 1, 2005

Outcome Measures

Primary Outcome Measures

  1. Change in cognition from baseline at week 24 []

  2. Global clinical impression of change from baseline at week 24 []

Secondary Outcome Measures

  1. Change in activities of daily living from baseline at week 24 []

  2. Change in behavioral symptoms from baseline at week 24 []

  3. Change in clinical staging from baseline at week 24 []

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Between the ages of 50 and 85 years old

  • Have contact with a responsible caregiver 3 or more days per week

  • Be male or a female who is surgically sterilized or one year post menopausal

Exclusion Criteria:
  • Current diagnosis of severe or unstable cardiovascular or other diseases

  • Current diagnosis of active, uncontrolled seizure disorder, Parkinson's disease or Alzheimer's disease

Contacts and Locations

Locations

Site City State Country Postal Code
1 Irvine California United States 92618
2 San Francisco California United States 94109
3 Boynton Beach Florida United States 33426
4 Miami Beach Florida United States 33140
5 Port Charlotte Florida United States
6 Indianapolis Indiana United States 46202
7 Des Moines Iowa United States 50314
8 St. Louis Missouri United States
9 Albuquerque New Mexico United States
10 New York New York United States 10003
11 Portland Oregon United States 97223
12 Allentown Pennsylvania United States 18103
13 Greensburg Pennsylvania United States 15601
14 Charleston South Carolina United States 29406
15 Austin Texas United States 78756
16 Houston Texas United States 77030
17 Bennington Vermont United States 05201
18 Graz Austria
19 Linz Austria
20 Wien Austria
21 Edmonton Alberta Canada
22 Ottawa Ontario Canada
23 Toronto Ontario Canada
24 Montreal Quebec Canada
25 Amiens France
26 Bordeaux France
27 Lille Cedex France
28 Marseille France
29 Montpellier Cedex France
30 Toulouse France
31 Tours Cedex France
32 Bautzen Germany
33 Berlin Germany
34 Bochum Germany
35 Chemnitz Germany
36 Eisenhuttenstadt Germany
37 Erlangen Germany
38 Freiburg Germany
39 Luedenscheid Germany
40 Osnabrueck Germany
41 Ancona Italy
42 Brescia Italy
43 Firenze Italy
44 Perugia Italy
45 Reggio Emilia Italy
46 Roma Italy
47 Vicenza Italy
48 Moscow Russian Federation
49 Saint-Petersburg Russian Federation
50 Barakaldo Spain
51 Barcelona Spain
52 Madrid Spain
53 Pamplona Spain
54 Saint Cugat del Valles Spain
55 Basel Switzerland
56 Lausanne Switzerland
57 Newcastle Upon Tyne Newcastle United Kingdom
58 Swindon Wiltshire United Kingdom
59 Bristol United Kingdom
60 Clydebank United Kingdom
61 East Sussex United Kingdom
62 Southampton United Kingdom
63 St Annes United Kingdom

Sponsors and Collaborators

  • Novartis Pharmaceuticals

Investigators

  • Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Novartis Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00099216
Other Study ID Numbers:
  • CENA713BIA05
First Posted:
Dec 10, 2004
Last Update Posted:
Nov 17, 2011
Last Verified:
Nov 1, 2011
Keywords provided by Novartis Pharmaceuticals
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 17, 2011